4 results about "PRIMARY BILIARY ATRESIA" patented technology

The present application relates to the technical field of vascular interventional treatment instruments, and discloses a system and method for the selective laser ablation of restenosis after the treatment of Budd-Chiari syndrome, comprising a controller, a pulse emission module and a reference element built into a catheter, the system is based on the reference element for periodic self-calibration, collects and processes the associated photoacoustic signals to identify the tissue type, and then realizes the selective ablation of the diseased tissue and the boundary self-stop when the healthy tissue is touched. The present application converts the traditional open-loop energy delivery into a closed-loop self-control process with real-time information interaction capability, so that the ablation operation end can in-situ perceive the tissue boundary and realize autonomous stop, thereby avoiding the problem of damaging the healthy tissue due to uncontrollable energy application, improving the safety of the operation, and having the advantages of high precision, few complications, repeatable treatment and the like.

The invention belongs to the technical field of biological medicine, and particularly relates to a biliary atresia differential diagnosis and prognosis marker and application thereof. The invention provides the application of the KRT17 expression level as a biliary atresia differential diagnosis and prognostic marker for the first time. KRT17 as a single marker has a relatively high diagnostic value (AUC = 0.880) for BA, the efficiency of KRT17 is superior to all conventional clinical liver function indexes, and when KRT17 is combined with alanine aminotransferase for use, the diagnostic accuracy can be further improved to AUC = 0.904, the KRT17 and CX3CL1 are optimally combined, and the AUC value is as high as 0.938. According to the technology, KRT17 is used as a novel biliary atresia differential diagnosis marker, the defects of an existing differential diagnosis system can be made up to a certain degree, the KRT17 is specifically and highly expressed in biliary atresia liver bile duct epithelial cells, normal control and disease control are not expressed, and therefore more accurate differential diagnosis can be provided clinically.

The invention belongs to the technical field of biological medicines, and particularly relates to application of parinumod in preparation of a medicine for treating biliary atresia. The invention discovers the treatment application of the S100A8 / A9 inhibitor in biliary atresia for the first time. The method comprises the following steps: inducing the formation of BA by intraperitoneal injection of RRV within 24 hours after a BALB / c newborn mouse is born, and after the RRV is injected from the intraperitoneal cavity, from the second day, injecting an S100A8 / A9 inhibitor Paquinimod (dosage: 50 mg / kg) into the intraperitoneal cavity of the mouse once every other day until the twelfth day. It can be observed that the survival time of the BA mouse treated by Paquinimod is prolonged, the jaundice symptom is relieved, the liver function index is obviously improved, and the infiltration number of inflammatory cells around the hepatic bile duct is obviously reduced. The invention provides a new potential target and a treatment strategy for treatment of BA.

This invention belongs to the field of biomedical technology, specifically relating to the application of spermine in the preparation of drugs for treating biliary atresia. This invention is the first to verify, through animal experiments (RRV mouse model), that spermine has a clear therapeutic effect on biliary atresia, achieving common bile duct recanalization and significantly reducing liver inflammation. Spermine itself possesses multiple functions including antioxidant, anti-inflammatory, and direct JAK1 inhibition, potentially working synergistically through multiple mechanisms such as mitigating initial damage and regulating immune responses, providing a more comprehensive pathological intervention than single-target inhibitors. Furthermore, spermine, as a known compound, has low production costs, and its application will greatly improve the accessibility of treatment.